Innovent's IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody, received FDA Fast Track Designation for treating advanced squamous non-small cell lung cancer after immunotherapy and chemotherapy failure.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.